HCRN GU17-289
A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289)
Learn more:
- clinicaltrials.gov: #NCT03501381
- News release
Linked In
You Tube
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter